Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;17(2):190-5.
doi: 10.5114/wo.2013.34624. Epub 2013 Apr 29.

Cardiac side effects of trastuzumab in breast cancer patients - single centere experiences

Joanna Huszno  1 , Dominika Leś, Danuta Sarzyczny-Słota, Elżbieta Nowara
Affiliations

Cardiac side effects of trastuzumab in breast cancer patients - single centere experiences

Joanna Huszno et al. Contemp Oncol (Pozn). 2013.

Abstract

Aim of the study: The aim of this study was to present our own experiences concerning risk factors for cardiac side effects in the study group.

Material and methods: The study was performed in 120 patients with HER2-overexpressing breast cancer who received immunotherapy in the Clinical and Experimental Oncology Department, between 2006 and 2011.

Results: LVEF reduction > 10% of the baseline fraction was observed in 10 (8%) patients. Symptomatic heart failure occurred in two individuals. Due to persistent cardiotoxicity five patients (4%) had to discontinue therapy prematurely. Risk factors for cardiac toxicity in the analyzed group included: previous radiotherapy to the left side of the chest (p = 0.05), higher BMI (p = 0.05), negative steroid receptor status (p = 0.045) and low baseline LVEF (p < 0.001). Patients receiving radiotherapy were more likely to develop cardiotoxicity if presenting older age (p = 0.0003).

Conclusions: Previous radiotherapy to the left side of the chest, negative steroid receptor status, high BMI and low baseline LVEF were associated with increased risk of cardiac dysfunction. There was no difference between patients receiving adjuvant therapy and those treated due to metastatic disease.

Keywords: breast cancer; cardiotoxicity; risk factors; trastuzumab.

PubMed Disclaimer

References

    1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82. - PubMed
    1. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122–31. - PubMed
    1. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–21. - PubMed
    1. Keefe DL. Trastuzumab – associated cardiotoxicity. Cancer. 2002;95:1592–600. - PubMed
    1. Freedman NJ, Ginsburg GS. Novel – and “neu” – therapeutic possibilities for heart failure. J Am Coll Cardiol. 2006;48:1448–50. - PubMed

LinkOut - more resources